A Comparison of Ondansetron and Transdermal Scopolamine Patches for Patients Identified to be at High Risk for the Development of Postoperative Nausea and Vomiting

2.50
Hdl Handle:
http://hdl.handle.net/10755/155688
Type:
Presentation
Title:
A Comparison of Ondansetron and Transdermal Scopolamine Patches for Patients Identified to be at High Risk for the Development of Postoperative Nausea and Vomiting
Abstract:
A Comparison of Ondansetron and Transdermal Scopolamine Patches for Patients Identified to be at High Risk for the Development of Postoperative Nausea and Vomiting
Conference Sponsor:Sigma Theta Tau International
Conference Year:2005
Author:Burkard, Joseph, DNSc, CRNA
P.I. Institution Name:Naval School of Health Sciences
Title:Director of Clinical Research
Risk factors have been identified which place a patient at a greater risk for developing postoperative nausea and vomiting (PONV). The purpose of this study was to determine if using a combination of TD scopolamine and IV ondansetron would be more efficacious in preventing PONV in a group of patients who are at high risk for PONV when compared to a similar group given IV ondansetron alone. This randomized, double blind trial was performed on 56 ASA I and II patients who were identified as high risk for the development of PONV. Prior to surgery all subjects randomly received either a transdermal scopolamine or placebo patch in addition to intravenous ondansetron. A significant difference was noted between the scopolamine (385 minutes) and the placebo (240 minutes) in the time until they experienced their first episode of nausea (p=0.032) and in the time of first emesis (498 minutes versus 324 minutes, respectively) (p=0.031). Subjects in the scopolamine group also required significantly less antiemetic treatment as compared to the placebo group while in the PACU or SDSU (9 versus 18 respectively) (p=0.016). VNRS scores for nausea were also noted to be significantly different between the groups at multiple time intervals (p< 0.05). It was also noted that those in the scopolamine group had a significantly lower incidence of PONV following discharge than the placebo group (1 versus 6, respectively) (p=0.043). This simple application of TD scopolamine has been shown to significantly reduce the incidence and severity of PONV in a group of patients who were at high risk for the development of PONV. This translated into a significant reduction in workload requirements for nursing personnel as well as an increase in overall patient comfort.
Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titleA Comparison of Ondansetron and Transdermal Scopolamine Patches for Patients Identified to be at High Risk for the Development of Postoperative Nausea and Vomitingen_GB
dc.identifier.urihttp://hdl.handle.net/10755/155688-
dc.description.abstract<table><tr><td colspan="2" class="item-title">A Comparison of Ondansetron and Transdermal Scopolamine Patches for Patients Identified to be at High Risk for the Development of Postoperative Nausea and Vomiting</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">2005</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Burkard, Joseph, DNSc, CRNA</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">Naval School of Health Sciences</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Director of Clinical Research</td></tr><tr class="item-email"><td class="label">Email:</td><td class="value">jburkard@mac.com</td></tr><tr><td colspan="2" class="item-abstract">Risk factors have been identified which place a patient at a greater risk for developing postoperative nausea and vomiting (PONV). The purpose of this study was to determine if using a combination of TD scopolamine and IV ondansetron would be more efficacious in preventing PONV in a group of patients who are at high risk for PONV when compared to a similar group given IV ondansetron alone. This randomized, double blind trial was performed on 56 ASA I and II patients who were identified as high risk for the development of PONV. Prior to surgery all subjects randomly received either a transdermal scopolamine or placebo patch in addition to intravenous ondansetron. A significant difference was noted between the scopolamine (385 minutes) and the placebo (240 minutes) in the time until they experienced their first episode of nausea (p=0.032) and in the time of first emesis (498 minutes versus 324 minutes, respectively) (p=0.031). Subjects in the scopolamine group also required significantly less antiemetic treatment as compared to the placebo group while in the PACU or SDSU (9 versus 18 respectively) (p=0.016). VNRS scores for nausea were also noted to be significantly different between the groups at multiple time intervals (p&lt; 0.05). It was also noted that those in the scopolamine group had a significantly lower incidence of PONV following discharge than the placebo group (1 versus 6, respectively) (p=0.043). This simple application of TD scopolamine has been shown to significantly reduce the incidence and severity of PONV in a group of patients who were at high risk for the development of PONV. This translated into a significant reduction in workload requirements for nursing personnel as well as an increase in overall patient comfort.</td></tr></table>en_GB
dc.date.available2011-10-26T14:04:45Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T14:04:45Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.